New England Journal of Medicine August 11, 2011

Prevention of HIV-1 Infection with Early Antiretroviral Therapy

Myron S. Cohen, Ying Q. Chen, Marybeth McCauley, Theresa Gamble, Mina C. Hosseinipour, et al. (HPTN 052 Study Team)

Bottom Line

In HIV-1 serodiscordant couples, early initiation of antiretroviral therapy by the infected partner reduced the risk of linked sexual transmission by 96%.

Key Findings

1. A total of 39 HIV-1 transmission events were observed, of which 28 were virologically linked to the infected partner [3.2.1].

2. Of the 28 linked transmissions, 1 occurred in the early-therapy group and 27 in the delayed-therapy group.

3. Early initiation of antiretroviral therapy (ART) was associated with a 96% reduction in the risk of linked HIV-1 transmission (Hazard Ratio 0.04; 95% CI, 0.01 to 0.27; P<0.001).

4. Clinical events (the primary composite clinical endpoint) occurred in 41 participants in the early-therapy group versus 65 in the delayed-therapy group (Hazard Ratio 0.59; 95% CI, 0.40 to 0.88; P=0.01).

5. The incidence of extrapulmonary tuberculosis was significantly lower in the early-therapy arm (3 cases) compared to the delayed-therapy arm (17 cases).

Study Design

Design

Randomized Controlled Trial

Open-Label

Sample

1,763

Patients

Duration

1.7 yr

Median

Setting

Multicenter, 9 countries

Population HIV-1 serodiscordant couples in which the HIV-1-positive partner had a CD4 count between 350 and 550 cells/mm³.

Intervention Early antiretroviral therapy (ART) initiated immediately.

Comparator Delayed antiretroviral therapy (ART) initiated after two consecutive CD4 counts fell below 250 cells/mm³ or upon the onset of an HIV-1-related symptom.

Outcome Linked HIV-1 transmission in HIV-1-negative partners and a composite clinical endpoint of the earliest occurrence of pulmonary tuberculosis, severe bacterial infection, a WHO stage 4 event, or death.

Study Limitations

• The median follow-up of 1.7 years at the time of this interim analysis was relatively short, requiring longer-term follow-up to confirm the durability of the effect.

• The vast majority of the couples enrolled (97%) were heterosexual, leaving initial uncertainty regarding the exact magnitude of risk reduction for men who have sex with men (MSM), which required subsequent trials to definitively address.

• The trial's open-label design could have influenced self-reported sexual behaviors and condom use, although the primary virologic transmission endpoint was strictly objective.

Clinical Significance

The HPTN 052 trial definitively proved the concept of 'Treatment as Prevention' (TasP). By demonstrating that viral suppression essentially eliminates the risk of sexual transmission, the study prompted major shifts in global health policies, leading the WHO to eventually recommend ART for all people living with HIV regardless of CD4 count. It also provided the foundational evidence for the global 'Undetectable = Untransmittable' (U=U) campaign.

Historical Context

Prior to 2011, antiretroviral therapy was primarily viewed as a tool for managing individual patient health and was frequently delayed until CD4 counts dropped below certain thresholds (e.g., <200 or <350 cells/mm³) to mitigate drug toxicity and resistance risks. While observational data suggested that ART could reduce transmission, public health guidelines required randomized trial data to validate TasP. The results of HPTN 052 were hailed as the 'Breakthrough of the Year' by Science in 2011 and radically reshaped the trajectory of the global HIV response.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does early initiation of antiretroviral therapy (ART) in an HIV-1 infected individual biologically reduce the risk of sexual transmission to a seronegative partner, and which specific laboratory marker is the primary surrogate for this reduced infectivity?

Key Response

ART inhibits viral replication, significantly reducing HIV RNA levels in blood and genital secretions. A suppressed viral load (e.g., undetectable or under 200 copies/mL) correlates directly with the inability to transmit the virus sexually, a foundational biological concept now widely recognized as U=U (Undetectable = Untransmittable).

Resident

A serodiscordant couple presents to your clinic; the HIV-positive partner was just diagnosed with a CD4 count of 450 cells/mm3. Based on the findings of this study, how should you counsel them regarding the initiation of ART and the need for additional preventive measures like PrEP for the negative partner?

Key Response

Based on HPTN 052, the positive partner should start ART immediately, regardless of CD4 count, to prevent transmission (96% risk reduction) and improve their own health. The resident should counsel that while waiting for the positive partner's viral load to become fully suppressed (which can take up to 6 months), the negative partner could be offered PrEP and they should continue using barrier protection.

Fellow

In this study, the efficacy endpoint was based specifically on 'linked' HIV-1 transmissions. How is linkage determined in such trials, and why is this distinction critical when evaluating the true efficacy of ART as prevention in serodiscordant couples?

Key Response

Linkage is determined using phylogenetic analysis of the HIV-1 env and pol gene sequences from both partners to ensure the virus in the newly infected partner originated directly from the index partner. Without distinguishing linked from unlinked transmissions (infections acquired from outside the partnership), the true biological efficacy of Treatment as Prevention (TasP) within the couple would be significantly underestimated.

Attending

HPTN 052 was a major catalyst for shifting global HIV management from CD4-stratified treatment to a universal 'test and treat' approach. How does this paradigm shift balance individual clinical benefit against public health transmission control, and what are the primary operational barriers to achieving the population-level impact demonstrated in this controlled trial?

Key Response

Early ART provides dual benefits: preserving individual immune function (reducing opportunistic infections and non-AIDS events) and halting population transmission. However, achieving trial-level efficacy in the real world requires overcoming the 'HIV care cascade' barriers: testing access, rapid linkage to care, long-term retention, and lifelong adherence to achieve sustained virologic suppression.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The Data and Safety Monitoring Board (DSMB) stopped the HPTN 052 trial early due to overwhelming efficacy. What are the methodological risks of halting a prevention trial early for efficacy, particularly regarding the estimation of long-term durability, behavioral risk compensation, and adverse event profiles?

Key Response

Stopping early for efficacy can lead to an overestimation of the treatment effect (a 'random high') and truncates long-term follow-up. This limits the ability of researchers to observe long-term ART toxicity, virologic failure rates over time, and potential 'risk compensation' (e.g., decreased condom use) that might alter the long-term effectiveness of the intervention in real-world settings.

Journal Editor

As a peer reviewer assessing the generalizability of these findings, how does the demographic composition of the study cohort (e.g., 97% heterosexual couples) affect the validity of extrapolating the 96% reduction in transmission risk to men who have sex with men (MSM) or people who inject drugs (PWID)?

Key Response

The transmission probability per act varies significantly by route, with receptive anal intercourse being much higher risk than vaginal intercourse. A critical reviewer would flag that while biological suppression is universal, the absolute efficacy and required adherence thresholds for TasP might differ in MSM or PWID, necessitating subsequent studies like PARTNER and Opposites Attract to confirm U=U across all populations.

Guideline Committee

How did the results of HPTN 052 influence the strength of recommendation and level of evidence for ART initiation in DHHS and WHO guidelines, and how does this study's focus on transmission risk harmonize with subsequent data (like the START trial) regarding individual morbidity?

Key Response

HPTN 052 provided Grade 1A evidence for ART to prevent transmission, prompting guidelines to recommend ART for all HIV-positive individuals with serodiscordant partners regardless of CD4 count. When later combined with the START trial (which proved individual health benefits of early ART), guidelines universally shifted to recommend ART for all people living with HIV, establishing the current 'Treat All' era.

Clinical Landscape

Noteworthy Related Trials

2015

START Trial

n = 4,685 · NEJM

Tested

Immediate initiation of ART

Population

HIV-positive adults with CD4+ count > 500 cells/mm3

Comparator

Deferred initiation of ART until CD4+ declined to 350 cells/mm3

Endpoint

Composite of serious AIDS-related events, serious non-AIDS-related events, or death

Key result: Immediate ART initiation reduced the risk of the primary composite endpoint by 57% compared to delayed therapy.

2015

PROUD Trial

n = 544 · Lancet

Tested

Daily oral TDF-FTC (PrEP)

Population

HIV-negative men who have sex with men at high risk of infection

Comparator

Deferred PrEP initiation (after 12 months)

Endpoint

Incidence of HIV infection

Key result: Daily PrEP reduced the risk of HIV infection by 86% in a real-world setting.

2016

PARTNER Trial

n = 1,166 · JAMA

Tested

Suppressive ART in the HIV-positive partner

Population

Serodiscordant couples engaging in condomless sex

Comparator

Observational cohort (no control)

Endpoint

Phylogenetically linked HIV transmission

Key result: There were zero cases of linked HIV transmission when the HIV-positive partner had an undetectable viral load.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis